THALAVIL

Thalavil® is indicated for the treatment of chronic hepatitis C (CHC) genotype 1 infection in adults.

The concomitant use of Thalavil® and P-gp inducers (e.g., rifampin, St. John’s wort) may significantly decrease ledipasvir and sofosbuvir plasma concentrations and may lead to a reduced therapeutic effect of Thalavil®. Therefore, the use of Thalavil® with P-gp inducers (e.g., rifampin or St. John’s wort) is not recommended.

The use of Thalavil® with other products containing sofosbuvir is not recommended.

SOGAZIL

Sogazil® (sofosbuvir) 400 mg is a nucleotide analog NS5B polymerase inhibitor for the treatment of chronic hepatitis C (CHC) as a component of a combination antiviral treatment regimen. Sogazil® efficacy has been established in subjects with HCV genotype 1, 2, 3 or 4 infection, including those with hepatocellular carcinoma meeting Milan criteria (awaiting liver transplantation) and those with HCV/HIV-1 co-infection. The following points should be considered when initiating treatment with Sogazil®:

Monotherapy of Sogazil® is not recommended for treatment of CHC.

Treatment regimen and duration are dependent on both viral genotype and patient population.

Treatment response varies based on baseline host and viral factors.

Contraindictions:

Sogazil® combination treatment with ribavirin or with peginterferon alfa plus ribavirin is contraindicated in women who are pregnant or may become pregnant and men whose female partners are pregnant because of the risk for birth defects and fetal death associated with ribavirin. Contraindications to peginterferon alfa and ribavirin also apply to Sogazil® combination treatment. Refer to the prescribing information of peginterferon alfa and ribavirin for a list of their contraindications.